ReviewLancet (London, England)2012
Cholera.
Review in Lancet (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 332 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
332 citing papers in PubMed, 4 syntheses or guidelines pooled it, 586 citations in OpenAlex.
- Associations of water quality with cholera in case-control studies: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Cholera in travellers: a systematic review.Journal of travel medicine · 2019Pooled it
- Guidelines for the management of paediatric cholera infection: a systematic review of the evidence.Paediatrics and international child health · 2018Pooled it
- A Systematic Review and Meta-Analysis of the Association between Water, Sanitation, and Hygiene Exposures and Cholera in Case-Control Studies.The American journal of tropical medicine and hygiene · 2018Pooled it
- The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.Frontiers in immunology · 2026Trial
- Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.PLoS neglected tropical diseases · 2018Trial
- Repurposing anti-phage defenses to differentially arrest the viral lifecycle reveals the regulatory logic of a parasitic satellite.mSystems · 2026Article
- A Comparative Analysis of Aging Across Causes of Death.Evolutionary applications · 2026Article
- Molecular characterization ofIJID regions · 2026Article
- Ordered assembly of themBio · 2026Article
- Seasonal variation, temporal trends, and factors associated with PCR-confirmed cholera in Goma city and surrounding health zones in Eastern Democratic Republic of the Congo, 2020-2024: a multilevel analysis.Tropical medicine and health · 2026Article
- Estimating time-varying cholera transmission and oral cholera vaccine effectiveness in Haiti and Cameroon, 2021-2023.BMJ open · 2026Article
- Factors associated with in-hospital mortality during the 2023 cholera outbreak in Hammanskraal, South Africa: a cross-sectional study.BMC infectious diseases · 2026Article
- Serotype and antimicrobial susceptibility patterns of Vibrio cholerae in cholera outbreak areas of East and Central Oromia Region, Ethiopia, 2024.BMC infectious diseases · 2026Article
- Article
- Diagnostic Accuracy of a Simple and Rapid Diagnostic Test RLDT for the Detection of Cholera in Bangladesh.Open forum infectious diseases · 2026Article
- Epidemiological evaluation of cholera outbreak dynamics in conflict-affected Central and Northwestern Tigray, northern Ethiopia: evidence from GEE analysis.Epidemiology and infection · 2026Article
- Controlled immobilization of single-domain antibodies using cellulose-binding modules for ABRSC advances · 2026Article
- Chromosome-borneIranian journal of microbiology · 2026Article
- Public health surveillance ofJournal of medical microbiology · 2026Article
272 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Cholera is an acute, secretory diarrhoea caused by infection with Vibrio cholerae of the O1 or O139 serogroup. It is endemic in more than 50 countries and also causes large epidemics. Since 1817, seven cholera pandemics have spread from Asia to much of the world. The seventh pandemic began in 1961 and affects 3-5 million people each year, killing 120,000. Although mild cholera can be indistinguishable from other diarrhoeal illnesses, the presentation of severe cholera is distinct, with pronounced diarrhoeal purging. Management of patients with cholera involves aggressive fluid replacement; effective therapy can decrease mortality from more than 50% to less than 0·2%. Antibiotic treatment decreases volume and duration of diarrhoea by 50% and is recommended for patients with moderate to severe dehydration. Prevention of cholera depends on access to safe water and sanitation. Two oral cholera vaccines are available and the most effective use of these in integrated prevention programmes is being actively assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.